Comparison of long term efficacy and cost-effectiveness of omalizumab in 150 mg and 300 mg doses in patients with chronic spontaneous urticaria
Since there is no significant difference between 150-300 mg omalizumab doses regarding long-term treatment efficacy and side effects in CSU patients, starting treatment with a 150 mg dose may be suitable. In patients who do not respond to 150 mg, the omalizumab dose can be increased to 300 mg. It will prevent unpredictable dose and time-dependent complications and will be a cost-effective approach even in strong economies.
Authors
- Fikriye Kalkan (ORCID: https://orcid.org/0000-0002-7199-436X)
- Özgür Kartal (ORCID: https://orcid.org/0000-0002-6666-581X)
- Ezgi Sönmez
- Fevzi Demirel (ORCID: https://orcid.org/0000-0002-9711-6821)
- Sait Yeşillik (ORCID: https://orcid.org/0000-0003-1160-1381)
- Mustafa İlker İnan (ORCID: https://orcid.org/0000-0002-7984-450X)
- Yasemin Akgul Balaban (ORCID: https://orcid.org/0000-0002-5654-1397)
Institutions
- Sağlık Bilimleri Üniversitesi (TR)
- University of Health Sciences Antigua (AG)
Publication Details
- Journal
- Anais Brasileiros de Dermatologia
- Published
- 2024-11-05
- DOI
- https://doi.org/10.1016/j.abd.2024.02.006
- Citations
- 2
- Primary Topic
- Urticaria and Related Conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.94